Akari Therapeutics has received written notification from Nasdaq that it has regained compliance with the minimum bid price requirement. The notification of compliance is a result of Akari’s ADSs having a closing bid price of $1.00 per share or greater for 10 consecutive business days. Akari’s ADSs continue to be listed and trade on the Nasdaq Capital Market under the symbol AKTX.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKTX:
- Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
- Akari Therapeutics announces establishment of headquarters in Boston
- Akari Therapeutics, Plc Announces ADS Ratio Change
- Akari Therapeutics announces ADS Ratio change
